pep2-SVKI

pep2-SVKI is a selective peptide inhibitor. pep2-SVKI inhibits the binding of AMPA-type glutamate receptor (GluA2) (C-terminal PDZ site) to glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP), and C-kinase interacting protein (PICK1). pep2-SVKI increases the amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD). pep2-SVKI can be used to study neurological diseases^[1][2][3][4]. In Vitro: pep2-SVKI (1 mM) reduces (Miniature Excitatory Postsynaptic Current) mEPSC amplitude at both −60 mV and +40 mV in the synaptic membrane of stellate cells^[1].

pep2-SVKI (100 μM) causes an increase in AMPAR-mediated (Excitatory Postsynaptic Current) EPSCs in hippocampal CA1 Neurons^[2].

pep2-SVKI (100 μM) prevents the expression of LTD in a (Protein Kinase C) PKC-Dependent Manner in hippocampal CA1 Neurons^[2].

pep2-SVKI increases tritium release induced by exposure to 100 μM AMPA in hippocampal synaptosomes prelabeled with (radiolabeled norepinephrine) [³H]NA and potentiates the AMPA-evoked release of [³H]NA in rat hippocampal synaptosomes^[3].

pep2-SVKI causes increase in the number of AMPARs exposed on the membrane in rat hippocampal synaptosomes^[3].

pep2-SVKI abolishes the sensitivity to Cyclothiazide (HY-101165) of the AMPA receptors controlling [³H]NA release^[3].